Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.
Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC®'s The Center for Biosimilars®, highlights recent progress, how the US market compares with Europe, and what remains to be seen.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Stakeholders Weigh In on the Key Biosimilar Developments of 2018
Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca
FDA Releases Biosimilar Action Plan
Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen
Pfizer Becomes Latest to Settle With AbbVie Over Humira
Read more about the stories in this podcast:
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen